Exportar registro bibliográfico


Metrics:

Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma (2017)

  • Authors:
  • USP affiliated authors: KALIL FILHO, ROBERTO - FM ; MARANHAO, RAUL CAVALCANTE - FCF
  • Unidades: FM; FCF
  • DOI: 10.1007/s12032-017-1009-z
  • Subjects: NANOPARTÍCULAS; CARCINOMA; OVÁRIO
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso à fonteDOI
    Informações sobre o DOI: 10.1007/s12032-017-1009-z (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    • Cor do Acesso Aberto: closed

    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      GRAZIANI, Silvia Regina; VITAL, Carolina Graziani; MORIKAWA, Aleksandra Tiemi; et al. Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma. Medical Oncology, Totowa, v. 34, p. 1-7 art. 151, 2017. Disponível em: < http://dx.doi.org/10.1007/s12032-017-1009-z > DOI: 10.1007/s12032-017-1009-z.
    • APA

      Graziani, S. R., Vital, C. G., Morikawa, A. T., Eyll, B. M. V., Fernandes Júnior, H. J., Kalil Filho, R., & Maranhão, R. C. (2017). Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma. Medical Oncology, 34, 1-7 art. 151. doi:10.1007/s12032-017-1009-z
    • NLM

      Graziani SR, Vital CG, Morikawa AT, Eyll BMV, Fernandes Júnior HJ, Kalil Filho R, Maranhão RC. Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma [Internet]. Medical Oncology. 2017 ; 34 1-7 art. 151.Available from: http://dx.doi.org/10.1007/s12032-017-1009-z
    • Vancouver

      Graziani SR, Vital CG, Morikawa AT, Eyll BMV, Fernandes Júnior HJ, Kalil Filho R, Maranhão RC. Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma [Internet]. Medical Oncology. 2017 ; 34 1-7 art. 151.Available from: http://dx.doi.org/10.1007/s12032-017-1009-z

    Referências citadas na obra
    Siegel RL, Miller KD, Jemal A. Cancer statistis 2017. CA Cancer J Clin. 2017;67:7–30.
    Engel J, Eckel R, Schubert-Fritschle G, Kerr J, Kuhn W, Diebold J, et al. Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. Eur J Cancer. 2002;38:2435–45.
    Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. J Epidemiol Biostat. 2001;6:107–38.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
    Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519–29.
    Covens A, Carey M, Bryson P, Verma S, Fung Kee Fung M, Johnston M. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol. 2002;85:71–80.
    Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099–106.
    Latorre A, De Lena M, Catino A, Crucitta E, Sambiasi D, Guida M, et al. Epithelial ovarian cancer: second and third line chemotherapy. Int J Oncol. 2002;21:179–86.
    Gubbi A, Kendrick JE, Finkler NJ. The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer. Expert Rev Anticancer Ther. 2014;14:1105–13.
    McLachlan J, Banerjee S. Olaparib for the treatment of epithelial ovarian cancer. Expert Opin Pharmacother. 2016;17:995–1003.
    Chiyoda T, Tsuda H, Nomura H, Kataoka F, Tominaga E, Suzuki A, et al. Effects of third-line chemotherapy for women with recurrent ovarian cancer who received platinum/taxane regimens as first-line chemotherapy. Eur J Gynaecol Oncol. 2010;31:364–8.
    Nishio S, Katsumata N, Matsumoto K, Tanabe H, Yonemori K, Kouno T, et al. Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy. J Cancer Res Clin Oncol. 2009;135:551–7.
    Liang XJ, Chen C, Zhao Y, Wang PC. Circumventing tumor resistance to chemotherapy by nanotechnology. Methods Mol Biol. 2010;596:467–88.
    Jabir NR, Tabrez S, Ashraf GM, Shakil S, Damanhouri GA, Kamal MA. Nanotechnology-based approaches in anticancer research. Int J Nanomed. 2012;7:4391–408.
    Maranhão RC, Garicochea B, Silva EL, Llacer PD, Pileggi FJ, Chamone DA. Increased plasma removal of microemulsions resembling the lipid phase of low-density lipoproteins (LDL) in patients with acute myeloid leukemia: a possible new strategy for the treatment of the disease. Braz J Med Biol Res. 1992;25:1003–7.
    Ho YK, Smith RG, Brown MS, Goldstein JL. Low-density lipoprotein (LDL) receptor activity in human acute myelogenous cells. Blood. 1978;52:1099–114.
    Brown MS, Goldstein JL. How LDL receptors influence cholesterol and atherosclerosis. Sci Am. 1984;251:58–66.
    Ades A, Carvalho JP, Graziani SR, Amancio RF, Souen JS, Pinotti JA, et al. Uptake of a cholesterol-rich emulsion by neoplastic ovarian tissues. Gynecol Oncol. 2001;82:84–7.
    Graziani SR, Igreja FA, Hegg R, Meneghetti C, Brandizzi LI, Barboza R, et al. Uptake of a cholesterol-rich emulsion by breast cancer. Gynecol Oncol. 2002;85:493–7.
    Dias ML, Carvalho JP, Rodrigues DG, Graziani SR, Maranhão RC. Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers. Cancer Chemother Pharmacol. 2007;59:105–11.
    Feio DCA, de Oliveira NCL, Pereira ELR, Morikawa AT, Muniz JAPC, Montenegro RC, et al. Organic effects of associating paclitaxel with a lipid-based nanoparticle system on a nonhuman primate, Cebus apella. Int J Nanomed. 2017;12:3827–37.
    Pires LA, Hegg R, Valduga CJ, Graziani SR, Rodrigues DG, Maranhão RC. Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study. Cancer Chemother Pharmacol. 2009;63:281–7.
    Azevedo CH, Carvalho JP, Valduga CJ, Maranhão RC. Plasma kinetics and uptake by the tumor of a cholesterol-rich microemulsion (LDE) associated to etoposide oleate in patients with ovarian carcinoma. Gynecol Oncol. 2005;97:178–82.
    Pinheiro KV, Hungria VT, Ficker ES, Valduga CJ, Mesquita CH, Maranhão RC. Plasma kinetics of a cholesterol-rich microemulsion (LDE) in patients with Hodgkin’s and non-Hodgkin’s lymphoma and a preliminary study on the toxicity of etoposide associated with LDE. Cancer Chemother Pharmacol. 2006;57:624–30.
    Maranhão RC, Graziani SR, Yamaguchi N, Melo RF, Latrilha MC, Rodrigues DG, et al. Association of carmustine with a lipid emulsion: in vitro, in vivo and preliminary studies in cancer patients. Cancer Chemother Pharmacol. 2002;49:487–98.
    Hungria VT, Latrilha MC, Rodrigues DG, Bydlowski SP, Chiattone CS, Maranhão RC. Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease. Cancer Chemother Pharmacol. 2004;53:51–60.
    Rodrigues DG, Maria DA, Fernandes DC, Valduga CJ, Couto RD, Ibañez OC, et al. Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. Cancer Chemother Pharmacol. 2005;55:565–76.
    Strickland DK, Kounnas MZ, Argraves WS. LDL receptor related protein: a multiligand receptor for lipoprotein and proteinase catabolism. FASEB J. 1995;9:890–8.
    Herz J, Strickland DK. LRP: a multifunctional scavenger and signaling receptor. J Clin Investig. 2001;108:779–84.
    Maier-Lenz H, Hauns B, Haering B, Koetting J, Mross K, Unger C, et al. Phase I study of paclitaxel administered as a 1-hour infusion: toxicity and pharmacokinetics. Semin Oncol. 1997;24(6 Suppl 19):S19-16–S19-19.
    Raber-Durlacher JE, Weijl NI, Abu Saris M, de Koning B, Zwinderman AH, Osanto S. Oral mucositis in patients treated with chemotherapy for solid tumors: a retrospective analysis of 150 cases. Support Care Cancer. 2000;8:366–71.
    Arbuck SG, Strauss H, Rowinsky E, Christian M, Suffness M, Adams J, et al. A reassessment of cardiac toxicity associated with Taxol. J Natl CancerInst Monogr. 1993;15:117–30.
    Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. Hypersensitivity reactions from Taxol. J Clin Oncol. 1990;8:1263–8.
    Zylberberg C, Matosevic S. Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape. Drug Deliv. 2016;23:3319–29.
    Sleep D. Albumin and its application in drug delivery. Expert Opin Drug Deliv. 2015;12:793–812.
    Krishnamurthy S, Vaiyapuri R, Zhang L, Chan JM. Lipid-coated polymeric nanoparticles for cancer drug delivery. Biomater Sci. 2015;3:923–36.
    Maranhão RC, Vital CG, Tavoni TM, Graziani SR. Clinical experience with drug delivery systems as tools to decrease the toxicity of anticancer chemotherapeutic agents. Expert Opin Drug Deliv. 2017;1:1–10.
    Waite CL, Roth CM. Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities. Crit Rev Biomed Eng. 2012;40:21–41.
    Sabbatini P, Sill MW, O’Malley D, Adler L, Secord AA. Gynecologic Oncology Group Study. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study. Gynecol Oncol. 2008;111:455–60.
    Bodnar L, Górnas M, Szczylik C. Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study. Gynecol Oncol. 2011;123:33–6.
    Pignata S, Lorusso D, Scambia G, Sambataro D, Tamberi S, Cinieri S, et al. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol. 2015;16:561–8.
    Hong SH, Lee S, Kim HG, Lee HJ, Jung KH, Lee SC, et al. Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10. Gynecol Oncol. 2015;136:212–7.
    Bruchim I, Jarchowsky-Dolberg O, Fishman A. Advanced (> second) line chemotherapy in the treatment of patients with recurrent epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2013;166:94–8.
    Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene. 2003;22:7280–95.

Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2021